MedPath

To find out the current status in the prescribing pattern of antidepressant drugs in patients wit first depressive episode in PGIMS Rohtak OPD.

Not Applicable
Conditions
Health Condition 1: G- Mental Health
Registration Number
CTRI/2023/07/055333
Lead Sponsor
Pt BD Sharma PGIMS Rohtak
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 All patients who are >= 18 years of age and are diagnosed with first depressive episode.

2 Male or female patients fulfilling ICD-10 criteria of first depressive episode.

3 Patients willing to provide written informed consent.

Exclusion Criteria

1 Patients with psychotic features.

2 History of any chronic physical or any other psychiatric illness.

3 Pregnant and lactating mothers

4 Patients with psychoactive substance use disorder

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1 Average number of drugs per encounter <br/ ><br>2 Percentage of drugs prescribed by <br/ ><br>generic name <br/ ><br>3 Percentage of encounters with an <br/ ><br>antidepressant drug prescribed <br/ ><br>4 Percentage of encounters with an <br/ ><br>injection prescribed <br/ ><br>5 Percentage of drugs prescribed from the <br/ ><br>drug formularys essential drug list <br/ ><br>(EDL)Timepoint: Drug prescriptions will be analyzed by WHO/INRUD drug prescription indicators at baseline.
Secondary Outcome Measures
NameTimeMethod
1. Naranjoâ??s adverse drug reactions <br/ ><br>(ADRs) probability scale for assessment <br/ ><br>of causality. <br/ ><br>2. The WHO-UMC Causality assessment <br/ ><br>scale <br/ ><br>3. Hartwig & Siegelâ??s Scale for <br/ ><br>assessment of the severity of adverse <br/ ><br>drug reactions (ADRs). <br/ ><br>4. Schumock and Thornton criteria for <br/ ><br>adverse drug reaction (ADRs) <br/ ><br>preventability assessment.Timepoint: Adverse Drugs Reactions (ADRs) will be <br/ ><br>analyzed using various scales for casualty, <br/ ><br>severity, & preventability at 6 weeks of <br/ ><br>study.
© Copyright 2025. All Rights Reserved by MedPath